Previous 10 | Next 10 |
Phoenix, Arizona--(Newsfile Corp. - November 25, 2019) - The Stock Day Podcast welcomed Biostage, Inc. (OTCQB: BSTG) ("the Company"), a bioengineering company that is developing next-generation esophageal implants. CEO of the Company, Jim McGorry, joined Stock Day host Everett Jolly. Jolly b...
Biostage, Inc. (BSTG) Q2 2019 Earnings Conference Call November 12, 2019 9:00 am ET Corporate Participants Peter Chakoutis - Vice President of Finance Jim McGorry - Chief Executive Officer Conference Call Participants Presentation Operator Thank you all for joining us...
Biostage ( OTC:BSTG ): Q3 GAAP EPS of -$0.33. More news on: Biostage, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOLLISTON, Mass. , Nov. 12, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a bioengineering company developing next-generation esophageal implants, today announced its financial results for the three and nine months ended September 30, 2019 . View full release with...
HOLLISTON, Mass. , Nov. 6, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a bioengineering company developing next-generation esophageal implants, announced today that it will report its financial results for the three and nine months ended September 30, 2019 in a press release...
HOLLISTON, Mass. , Oct. 30, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a bioengineering company developing next-generation esophageal implants, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration...
Phoenix, Arizona--(Newsfile Corp. - September 3, 2019) - The Stock Day Podcast welcomed Jim McGorry of Biostage, Inc. (OTCQB: BSTG) ("the Company"), a biotechnology startup developing bioengineered organ implants based on its Cellspan technology that combines a proprietary biocompatible scaffo...
Biostage, Inc. (BSTG) Q2 2019 Earnings Conference Call Aug 13, 2019 9:00 AM ET Company Participants Jim McGorry - Chief Executive Officer Peter Chakoutis - Vice President of Finance Conference Call Participants Presentation Operator Thank you all for joining us this ...
Biostage ( OTC:BSTG ): Q2 GAAP EPS of -$0.37. More news on: Biostage, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOLLISTON, Mass. , Aug. 13, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial re...
News, Short Squeeze, Breakout and More Instantly...
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024. Received $0.5 million in convertible debt from Company’s CEO in February 2024. Hollisto...
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following Colectomy Established a Collaboration with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproduct...
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate o...